Compare Amylx Pharmaceuticals Inc (AMLX) vs Mongodb Inc (MDB) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

MongoDB (MDB) trades at $398.8, up 7.78% in the last session, reflecting strong momentum near the consensus price target of $400.39. The stock shows bullish technical signals with support at $384 and resistance at $407. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent quarters have consistently beaten EPS estimates, and analyst sentiment is overwhelmingly positive with 82% buy ratings.

The outlook for MDB is optimistic due to accelerating revenue growth and AI-driven demand, but risks include persistent losses, high valuation multiples, and competitive pressures. Institutional buying and bullish technical trends support near-term upside, yet profitability challenges warrant caution for long-term investors.